Melittin-Loaded Nanoparticle Microneedles Targeting M1 Macrophage for Arthritis Treatment
Molecular Pharmaceutics · 07.07.2025 · 22 (7) · 3679-3692
DOI: 10.1021/acs.molpharmaceut.4c01383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 29.05.2025. Verfasst von Jitong Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republi…. Hauptthemen laut MEDLINE: Melitten, Macrophages, Nanoparticles, Arthritis, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Shanghai University of Traditional Chinese Medicine, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Arthritis is a joint inflammatory disease with multiple types that significantly compromises patients' quality of life. Current therapeutic efficiency is frequently constrained by the necessity for high dosages, the requirement for frequent administration, substantial side effects, and the risk of drug resistance. New therapeutic strategies are urgently needed. Melittin (Mel), a principal component of bee venom, has potent anti-inflammatory properties; however, its clinical application is limited by its hemolytic activity. To overcome the shortage, we developed targeted nanoparticles carrying Mel (MSC@NP-FA) with 68.3 ± 1.8% encapsulation efficiency, which were loaded within a microneedle (MN) to create MSC@NP-FA-MN. This strategy allows for precise anti-inflammatory therapy while reducing the risk of hemolysis. Both in vitro and in vivo studies demonstrated that MSC@NP-FA has lower hemolytic activity than Mel (p < 0.0001) and can target inflammatory macrophages to exert anti-inflammatory effects. In vitro transdermal test showed that more nanoparticles were delivered by the MNs (84.32 ± 6.97%) than bare nanoparticles (26.30 ± 2.55%) within 24 h. Furthermore, MSC@NP-FA-MN exhibited significant therapeutic efficacy without systemic toxicity or skin irritation in an adjuvant-induced arthritis (AIA) mouse model. Our findings highlight MSC@NP-FA-MN as a promising drug delivery system and suggest a new approach for safe and precise arthritis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China.
- Engineering Research Center of Modern Preparation Technology of TCM, Ministry of Education, Shanghai 201203, People's Republic of China.
ORCID-Profile: Jitong Wang, Ruixiang Li, Ruofei Du
Förderung
- Shanghai University of Traditional Chinese Medicine
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Wang, J., Zhao, F., Zhang, Y., Wen, Y., Wang, W., Hu, J., Qiao, C., Li, R., & Du, R. (2025). Melittin-Loaded Nanoparticle Microneedles Targeting M1 Macrophage for Arthritis Treatment. Molecular Pharmaceutics, 22(7), 3679-3692. https://doi.org/10.1021/acs.molpharmaceut.4c01383
Vancouver
Wang J, Zhao F, Zhang Y, Wen Y, Wang W, Hu J, et al. Melittin-Loaded Nanoparticle Microneedles Targeting M1 Macrophage for Arthritis Treatment. Molecular Pharmaceutics. 2025;22(7):3679-3692. doi:10.1021/acs.molpharmaceut.4c01383
BibTeX
@article{Wang2025,
author = {Wang, Jitong and Zhao, Fan and Zhang, Yu and Wen, Yuting and Wang, Wenxu and Hu, Jinru and Qiao, Chun and Li, Ruixiang and Du, Ruofei},
title = {Melittin-Loaded Nanoparticle Microneedles Targeting M1 Macrophage for Arthritis Treatment},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {7},
pages = {3679--3692},
doi = {10.1021/acs.molpharmaceut.4c01383}
}
EUVIMED